Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Elite Pharmaceuticals (OTCQB: ELTP) reported financial results for Q3 FY2025 ended December 31, 2024. The company saw consolidated revenues of $14.4 million, representing an 8% decrease ($1.2 million) compared to the same period last year. Operating profits declined by 69% to $1.1 million, a $2.4 million decrease from the previous year.
The company attributed the performance decline to timing differences during the December holiday period, which resulted in shipment delays into the first week of January 2025. Elite Pharmaceuticals, which specializes in developing, manufacturing, and distributing niche generic products, has scheduled a conference call for February 14, 2025, at 11:30 AM EST to discuss these results and provide business updates.
Elite Pharmaceuticals (OTCQB: ELTP) ha riportato i risultati finanziari per il terzo trimestre dell'anno fiscale 2025, conclusosi il 31 dicembre 2024. L'azienda ha registrato ricavi consolidati di 14,4 milioni di dollari, con una diminuzione dell'8% (1,2 milioni di dollari) rispetto allo stesso periodo dell'anno precedente. I profitti operativi sono diminuiti del 69%, scendendo a 1,1 milioni di dollari, con una diminuzione di 2,4 milioni di dollari rispetto all'anno scorso.
L'azienda ha attribuito il calo delle performance a differenze temporali durante il periodo delle festività di dicembre, che hanno comportato ritardi nelle spedizioni nella prima settimana di gennaio 2025. Elite Pharmaceuticals, specializzata nello sviluppo, produzione e distribuzione di prodotti generici di nicchia, ha programmato una conferenza telefonica per il 14 febbraio 2025, alle 11:30 AM EST, per discutere di questi risultati e fornire aggiornamenti aziendali.
Elite Pharmaceuticals (OTCQB: ELTP) reportó los resultados financieros del tercer trimestre del año fiscal 2025, que finalizó el 31 de diciembre de 2024. La compañía vio ingresos consolidados de 14.4 millones de dólares, lo que representa una disminución del 8% (1.2 millones de dólares) en comparación con el mismo período del año pasado. Las ganancias operativas cayeron un 69% a 1.1 millones de dólares, una disminución de 2.4 millones de dólares con respecto al año anterior.
La compañía atribuyó la disminución del rendimiento a diferencias de tiempo durante el período de vacaciones de diciembre, lo que resultó en retrasos en los envíos a la primera semana de enero de 2025. Elite Pharmaceuticals, que se especializa en el desarrollo, fabricación y distribución de productos genéricos de nicho, ha programado una conferencia telefónica para el 14 de febrero de 2025, a las 11:30 AM EST, para discutir estos resultados y proporcionar actualizaciones comerciales.
엘리트 제약 (OTCQB: ELTP)는 2024년 12월 31일 종료된 2025 회계연도 3분기 재무 결과를 보고했습니다. 회사는 통합 수익이 1,440만 달러로, 지난해 같은 기간에 비해 8% 감소(120만 달러 감소)를 기록했습니다. 운영 이익은 69% 감소하여 110만 달러에 달하며, 이는 지난해보다 240만 달러 감소한 수치입니다.
회사는 성과 감소를 12월 홀리데이 기간 동안의 시차로 인한 것으로 설명했으며, 이로 인해 2025년 1월 첫 주로의 발송 지연이 발생했습니다. 틈새 제네릭 제품의 개발, 제조 및 유통을 전문으로 하는 엘리트 제약은 2025년 2월 14일 오전 11시 30분 EST에 이 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜을 예정하고 있습니다.
Elite Pharmaceuticals (OTCQB: ELTP) a publié ses résultats financiers pour le troisième trimestre de l'exercice 2025, se terminant le 31 décembre 2024. L'entreprise a enregistré des revenus consolidés de 14,4 millions de dollars, soit une baisse de 8 % (1,2 million de dollars) par rapport à la même période l'année précédente. Les bénéfices d'exploitation ont chuté de 69 % à 1,1 million de dollars, soit une baisse de 2,4 millions de dollars par rapport à l'année précédente.
L'entreprise a attribué cette baisse de performance à des différences de timing pendant la période des fêtes de décembre, ce qui a entraîné des retards d'expédition dans la première semaine de janvier 2025. Elite Pharmaceuticals, qui se spécialise dans le développement, la fabrication et la distribution de produits génériques de niche, a prévu une conférence téléphonique pour le 14 février 2025 à 11h30 EST afin de discuter de ces résultats et de fournir des mises à jour sur l'entreprise.
Elite Pharmaceuticals (OTCQB: ELTP) hat die finanziellen Ergebnisse für das dritte Quartal des Geschäftsjahres 2025, das am 31. Dezember 2024 endete, bekannt gegeben. Das Unternehmen verzeichnete konsolidierte Einnahmen von 14,4 Millionen US-Dollar, was einem Rückgang von 8% (1,2 Millionen US-Dollar) im Vergleich zum Vorjahreszeitraum entspricht. Die Betriebsgewinne sanken um 69% auf 1,1 Millionen US-Dollar, was einem Rückgang von 2,4 Millionen US-Dollar gegenüber dem Vorjahr entspricht.
Das Unternehmen führte den Rückgang der Leistung auf zeitliche Unterschiede während der Dezember-Urlaubszeit zurück, die zu Versandverzögerungen in der ersten Januarwoche 2025 führten. Elite Pharmaceuticals, das sich auf die Entwicklung, Herstellung und den Vertrieb von Nischen-Generika spezialisiert hat, hat eine Telefonkonferenz für den 14. Februar 2025 um 11:30 Uhr EST angesetzt, um diese Ergebnisse zu besprechen und Unternehmensupdates bereitzustellen.
- Maintained profitability with $1.1 million in operating profits
- Strong revenue base of $14.4 million for the quarter
- 8% decrease in consolidated revenues (-$1.2 million) year-over-year
- 69% decline in operating profits (-$2.4 million) year-over-year
- Shipment delays affecting Q3 performance
Conference Call Scheduled for Friday, February 14 at 11:30 AM EST
Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's fiscal year ending on March 31, 2025 ("Third Quarter").
Consolidated revenues for the three months ended December 31, 2024, were
Conference Call Information
Elite's management will host a conference call to discuss the Third Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | February 14, 2025 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EST on Thursday, February 13, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite's Third Quarter of Fiscal Year 2025 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA-registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240670
FAQ
What was Elite Pharmaceuticals (ELTP) revenue for Q3 FY2025?
How much did ELTP's operating profits decline in Q3 FY2025?
What caused the revenue decline for ELTP in Q3 FY2025?
When is Elite Pharmaceuticals (ELTP) Q3 earnings conference call?
